ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?
ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio.
Amneal Receives U.S. FDA Approval for Iohexol Injection - Amneal Pharmaceuticals ( NASDAQ:AMRX )
BRIDGEWATER, N.J., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( "Amneal" or the "Company" ) ( NASDAQ:AMRX ) today announced the U.S. Food and Drug Administration ( FDA ) has approved the Company's iohexol injection ( 300 mg Iodine/mL ) , the first generic version of GE ...
Implied Volatility Surging for Amneal Pharmaceuticals Stock Options
Investors need to pay close attention to AMRX stock based on the movements in the options market lately.
Amneal Pharmaceuticals ( AMRX ) Beats Q3 Earnings and Revenue Estimates
Amneal (AMRX) delivered earnings and revenue surprises of +30.77% and +1.41%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Amneal Reports Third Quarter 2025 Financial Results
‒ Q3 2025 Net Revenue of $785 million. GAAP Net Income of $2 million. Diluted Income per Share of $0.01 ‒‒ Adjusted EBITDA of $160 million. Adjusted Diluted EPS of $0.17 ‒‒ Updated 2025 Full Year Guidance ...
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol - Amneal Pharmaceuticals ( NASDAQ:AMRX )
BRIDGEWATER, N.J., Oct. 29, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( "Amneal" or the "Company" ) today announced that the U.S.
Neurocrine Biosciences ( NBIX ) Q3 Earnings and Revenues Top Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of +29.11% and +6.73%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
BioCryst Pharmaceuticals ( BCRX ) Earnings Expected to Grow: Should You Buy?
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amneal Launches Brekiya® - the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
BRIDGEWATER, N.J., Oct. 27, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( Nasdaq: AMRX ) ( "Amneal" or the "Company" ) today announced the U.S. commercial launch of Brekiya® ( dihydroergotamine mesylate ) injection, the first and only ready-to-use dihydroergotamine ( DHE ) ...
Analysts Estimate Amneal Pharmaceuticals ( AMRX ) to Report a Decline in Earnings: What to Look Out for
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer
New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companies New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companies ...
Global Anti-Parkinson's Drugs Markets Projected to Reach $9.2 Billion by the End of 2030
Boston, Oct. 16, 2025 ( GLOBE NEWSWIRE ) -- According to the latest study from BCC Research, "Anti-Parkinson's Drugs: Global Markets to 2030" is projected to grow from $6.1 billion in 2025 to $9.2 billion by the end of 2030, at a compound annual growth rate ( CAGR ) of 8.6% from 2025 to 2030.
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs - Amphastar Pharma ( NASDAQ:AMPH ) , Amneal Pharmaceuticals ( NASDAQ:AMRX )
The Trump administration is reportedly planning to exclude imported generic drugs from tariffs.
Are Investors Undervaluing Amneal Pharmaceuticals ( AMRX ) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus
Amneal Pharmaceuticals, Leidos and Vishay Precision stand out as Zacks highlights amid market volatility and shifting rate expectations.
Xeris Biopharma Holdings, Inc. ( XERS ) Hits Fresh High: Is There Still Room to Run?
Xeris Biopharma (XERS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Are Medical Stocks Lagging Amneal Pharmaceuticals ( AMRX ) This Year?
Here is how Amneal Pharmaceuticals (AMRX) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
Amneal to Report Third Quarter 2025 Results on October 30, 2025 - Amneal Pharmaceuticals ( NASDAQ:AMRX )
BRIDGEWATER, N.J., Sept. 30, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( NASDAQ:AMRX ) ( "Amneal" or the "Company" ) , a global biopharmaceutical company, today announced that the Company will release its third quarter 2025 financial results on Thursday, October 30, 2025, prior to ...
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® ( omalizumab )
Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for ...
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension - Amneal Pharmaceuticals ( NASDAQ:AMRX )
Another addition to Amneal's growing complex injectables portfolio reflects leadership in advanced development and manufacturing of complex pharmaceuticals BRIDGEWATER, N.J., Sept. 04, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( "Amneal" or the "Company" ) today announced the U.S.
Wall Street Analysts Think Amneal ( AMRX ) Could Surge 25.52%: Read This Before Placing a Bet
The consensus price target hints at a 25.5% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Rigel Pharmaceuticals, Inc. ( RIGL ) Soars to 52-Week High, Time to Cash Out?
Rigel (RIGL) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Wall Street Analysts See a 27.66% Upside in Amneal ( AMRX ) : Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 27.7% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Are Medical Stocks Lagging Boston Scientific ( BSX ) This Year?
Here is how Boston Scientific (BSX) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
Here's Why Momentum in Amneal ( AMRX ) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Amneal (AMRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Amneal ( AMRX ) Q2 EPS Jumps 56%
Amneal Pharmaceuticals ( NASDAQ:AMRX ) , a developer and manufacturer of specialty and generic pharmaceuticals, released its second quarter earnings on August 5, 2025. The company reported stronger-than-expected profitability, as non-GAAP EPS of $0.25 exceeded analyst estimates, with adjusted ...
Knight Therapeutics Announces Regulatory Submission of CREXONT® ( Carbidopa and Levodopa ) Extended-Release Capsules in Mexico
MONTREAL, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc., ( TSX: GUD ) ( "Knight" ) a pan-American ( ex-USA ) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V., has submitted a marketing authorization ...
Amneal Pharmaceuticals ( AMRX ) Q2 Earnings Top Estimates
Amneal (AMRX) delivered earnings and revenue surprises of +38.89% and -0.15%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Amneal Reports Second Quarter 2025 Financial Results
‒ Q2 2025 Net Revenue of $725 million. GAAP Net Income of $22 million. Diluted Income per Share of $0.07 ‒‒ Adjusted EBITDA of $184 million. Adjusted Diluted EPS of $0.25 ‒‒ Raising 2025 Full Year Guidance ‒‒ Full Debt Refinancing Reduces Interest Cost and Extends Maturities to ...
Viatris Poised to Report Q2 Earnings: What's in Store for the Stock?
VTRS braces for Q2 results as branded drug growth in Europe and China offsets generic headwinds in North America.
Nektar Gears Up to Report Q2 Earnings: What's in the Cards?
NKTR is due to report second-quarter results. Investors await fresh updates on rezpeg's progress across autoimmune trials.
Bio-Techne Q4 Earnings Preview: What's in Store for the Stock?
TECH eyes modest Q4 growth as strong reagent and instrumentation demand offsets NIH and tariff concerns.
Amneal ( AMRX ) is an Incredible Growth Stock: 3 Reasons Why
Amneal (AMRX) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Amneal Pharmaceuticals ( AMRX ) Earnings Expected to Grow: Should You Buy?
Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think Amneal ( AMRX ) Could Surge 43.82%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 43.8% in Amneal (AMRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Is Amneal Pharmaceuticals ( AMRX ) Outperforming Other Medical Stocks This Year?
Here is how Amneal Pharmaceuticals (AMRX) and Boston Scientific (BSX) have performed compared to their sector so far this year.
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032 - Amneal Pharmaceuticals ( NASDAQ:AMRX )
BRIDGEWATER, N.J., July 21, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( "Amneal" ) AMRX announced that its subsidiary, Amneal Pharmaceuticals LLC ( the "Issuer" ) , is seeking to borrow $1.800 billion aggregate principal amount of new seven-year term B loans ( the "new term B ...
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
BRIDGEWATER, N.J., July 21, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( "Amneal" ) ( Nasdaq: AMRX ) announced that its subsidiary, Amneal Pharmaceuticals LLC ( the "Issuer" ) , is seeking to borrow $1.800 billion aggregate principal amount of new seven-year term B loans ( the "new ...
Amneal Reports Certain Preliminary Second Quarter 2025 Financial Results
- Results Reflect Continued Financial Strength and ...
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® ( Carbidopa and Levodopa ) Extended-Release Capsules in Canada
MONTREAL, July 18, 2025 ( GLOBE NEWSWIRE ) -- Knight Therapeutics Inc., ( TSX: GUD ) ( "Knight" ) a pan-American ( ex-USA ) specialty pharmaceutical company, announced today that Knight's New Drug Submission ( NDS ) for CREXONT® has been accepted for review by Health Canada.
Indivior ( INDV ) Moves 5.7% Higher: Will This Strength Last?
Indivior (INDV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Has Amneal Pharmaceuticals ( AMRX ) Outpaced Other Medical Stocks This Year?
Here is how Amneal Pharmaceuticals (AMRX) and AtriCure (ATRC) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Amneal Pharmaceuticals ( AMRX ) This Year?
Here is how Amneal Pharmaceuticals (AMRX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension
BRIDGEWATER, N.J., June 12, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( "Amneal" or the "Company" ) today announced the U.S. Food and Drug Administration ( FDA ) approval of prednisolone acetate ophthalmic suspension, 1% sterile which references Pred Forte®.
Catalyst Pharmaceuticals, Inc. ( CPRX ) Hits Fresh High: Is There Still Room to Run?
Catalyst (CPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Wall Street Analysts Believe Amneal ( AMRX ) Could Rally 54.36%: Here's is How to Trade
The consensus price target hints at a 54.4% upside potential for Amneal (AMRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
3 Reasons Growth Investors Will Love Amneal ( AMRX )
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
Amneal Receives U.S. FDA Approval for Brekiya® ( dihydroergotamine mesylate ) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults
BRIDGEWATER, N.J., May 15, 2025 ( GLOBE NEWSWIRE ) -- Amneal Pharmaceuticals, Inc. ( Nasdaq: AMRX ) ( "Amneal" or the "Company" ) today announced that the U.S. Food and Drug Administration ( FDA ) has approved Brekiya® ( dihydroergotamine mesylate ) injection, the first and only dihydroergotamine ...
Does Amneal ( AMRX ) Have the Potential to Rally 54.16% as Wall Street Analysts Expect?
The mean of analysts' price targets for Amneal (AMRX) points to a 54.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here is Why Growth Investors Should Buy Amneal ( AMRX ) Now
Amneal (AMRX) could produce exceptional returns because of its solid growth attributes.
